H.C. Wainwright analyst Patrick Trucchio maintains $Sangamo Therapeutics (SGMO.US)$ with a buy rating, and maintains the target price at $10.
According to TipRanks data, the analyst has a success rate of 35.4% and a total average return of 16.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following Sangamo's latest quarterly report, there's an anticipation of a significant development pathway for the Fabry program aligned with the FDA. The subsequent discussions centered on the program's future, with partnership negotiations reportedly in the advanced phase. The expectation is set for potentially favorable data outcomes by the third quarter of 2025, followed by anticipated regulatory approval in 2026, and a partnership deal announcement is expected imminently.
The firm anticipates that the formation of partnerships concerning the Fabry program and the comprehensive data from the pivotal study will act as primary catalysts. It is believed that the potential rise in the stock's value will be propelled by the proof of concept for the company's proprietary ZFP transcription factor neurology programs.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
H.C. Wainwright分析師Patrick Trucchio維持$Sangamo Therapeutics (SGMO.US)$買入評級，維持目標價10美元。
根據TipRanks數據顯示，該分析師近一年總勝率為35.4%，總平均回報率為16.7%。
此外，綜合報道，$Sangamo Therapeutics (SGMO.US)$近期主要分析師觀點如下：
根據Sangamo的最新季度報告，有一個與FDA對齊的Fabry項目的重要開發路徑的預期。隨後的討論集中在該項目的未來，合作談判據報道處於愛文思控股階段。預計到2025年第三季度可能會有有利數據結果，隨後預計將在2026年獲得監管批准，同時合作協議可能很快會宣佈。
公司預計，有關Fabry項目合作伙伴關係的形成以及關鍵研究的全面數據將是主要催化劑。相信公司獨有的ZFP轉錄因子神經學項目的概念驗證將推動股價的潛在上升。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
